Stocks / Healthcare

GlaxoSmithKline PLC ADR

GSK Stock Report
Current Price
XXXX
Analyst Target Price
$39.03
Market Cap
XXXX
Updated
September 10, 2025
Analysts
8

GlaxoSmithKline PLC ADR Stock Overview

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the … More details ➜
1 Year Price Range
Low $30.68 Current High $42.16
PinkLion Scores

Fundamentals Summary

P/E Ratio
18.29x
P/S Ratio
2.60x
Net Income
Revenue
Market Cap

Net Income & Revenue

Last Reported Earnings
June 30, 2025
Earnings per share (EPS) $2.23
Gross Margin 71.69%
Net Profit Margin 10.82%
Debt/Equity Ratio 64.51%

Dividends

Current Dividend Yield
4.04%
Payout Ratio
38.21%
Forward Dividend Yield
4.04%

Price History

Track historical stock performance, price trends, and volatility for GSK to see how the stock has performed over time.
YTD
1 Year
5 Years
All

Valuation Summary

We estimate a fair price for GSK by projecting its future cash flows and discounting them back to today with a XXXXX model.

About the Company

IPO Date
July 9, 1986
Employees
68,629
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
USA
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.